Does Intravesical Povidone-Iodine Reduce Risk of Surgical Site Infection in Patients with Chronic Urinary Catheters? Results of a Prospective Randomised Controlled Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202511672164284

Enrollment

140

Registered

2025-11-14

Start date

2024-01-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Povidone Iodine group A

saline group B

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1-Established clinical diagnosis of benign prostatic hyperplasia or urethral stricture prior to surgery 2-Indwelling urethral catheter or suprapubic cystostomy tube for > 1 month prior to day of surgery 3-Age = 10 years old

Exclusion criteria

Exclusion criteria: Known allergy to lodine or lodine containing solutions Severely immunocompromised or undergoing concurrent immunosuppressive therapy. If HIV positive, Viral load >50 copies or CDA count <200 cells/cc3 Concurrent visceral perforation. Concurrent skin, blood or visceral infection

Design outcomes

Primary

Measure	Time frame
To evaluate the effectiveness of preoperative bladder irrigation with PI in reducing the incidence of SSI for chronically catheterized patients undergoing surgical treatment for benign prostatic hyperplasia or urethral stricture.	—

Secondary

Measure	Time frame
comparing number of SSI per given follow-up duration	—

Countries

Malawi

Contacts

Public ContactJoseph Mkandawire

General Surgery Resident

joe18wire@gmail.com+265888299480

Outcome results